This is the first time Biocartis has collaborated withWellcome Trust Sanger Institute and Philips Research. Ultimately, the test theydesign is envisioned as being broadly applicable for all types of solid,metastatic tumors, according to Nader Donzel, chief technology officer atBiocartis and head of its DMAT business unit. DMAT, which stands for DynamicMulti-Analyte Technology, is the codename of Biocartis' Multiplex AssayPlatform, which enables accelerated development of multi-analyte assays,reduces time-to-result and hands-on time, and provides high-quality protein andnucleic acid-based biomarker analysis.
"From a timing perspective, this collaboration is wellplaced in the sense that as a company, you find yourself at a juncture—as weare now—where you feel that your technology offers significant advantages overexisting technology, but you don't have the full package of funding, data orsupport that you need," Donzel tells ddn."So, coming into this collaboration was an excellent way to demonstrate andvalidate Biocartis' claims of its technology and have access to patient samplesand expanded opportunities. For the other partners, it opens for them aclinical perspective that they cannot achieve with other technologies andoffers them a new way of looking at the solutions that can get them faster andbetter clinical data."
This person does not yet have a bio.View Full Profile
